Intraepidermal Squamous Cell Carcinoma

Intraepidermal squamous cell carcinoma (SCC in situ, Bowen disease) is an early, non-invasive skin cancer confined to the epidermis. Cells look malignant under the microscope but haven’t broken through the basement membrane; that’s why treatment is highly curative and scarring-sparing options (e.g., photodynamic therapy or topical field therapy) are often appropriate. Common signs are slowly enlarging, well-demarcated, scaly red-brown plaques, often on sun-exposed skin or lower legs; diagnosis is confirmed by biopsy. Left untreated, a minority can progress to invasive SCC. DermNet®+1

Intraepidermal squamous cell carcinoma means there are cancer-type squamous cells growing only in the outer skin layer (the epidermis). They have not broken through the basement membrane into the deeper dermis. Because the cells stay “in place,” doctors also call it “carcinoma in situ” or “stage 0” squamous cell carcinoma. If it is not treated, a small number of cases can slowly turn into invasive squamous cell carcinoma that can grow deeper and rarely spread. Cancer.gov+2DermNet®+2

---

Other names

• Squamous cell carcinoma in situ (SCCIS)

• Bowen disease / Bowen’s disease (the classic cutaneous form)

• Intraepidermal carcinoma (IEC)

• Erythroplasia of Queyrat (SCC in situ on the glans penis/penile mucosa)

• Bowenoid papulosis (HPV-related, genital papules with in-situ histology)
  These names all refer to the same basic idea: abnormal squamous cells limited to the epidermis. DermNet®+2bad.org.uk+2

---

Types

1. Classic cutaneous Bowen disease – a slow-growing, well-defined, red, scaly patch or plaque on sun-exposed skin such as the legs, face, scalp, or trunk. ACD

2. Erythroplasia of Queyrat – a velvety red patch on the glans penis or prepuce; linked to high-risk HPV and usually in uncircumcised men. Medscape+1

3. Bowenoid papulosis – multiple small brown-to-reddish genital papules with SCC-in-situ changes under the microscope; strongly HPV-related. bad.org.uk

4. Pigmented SCC in situ – looks brown or black because of extra melanin; still an in-situ lesion on histology. DermNet®

5. Pagetoid SCC in situ – scattered large atypical cells high in the epidermis that can mimic Paget disease or melanoma in situ; special stains help to confirm. DermNet®

6. Nail-unit SCC in situ – periungual/under-nail disease, sometimes HPV-associated; may show persistent onycholysis, erythronychia, or warty changes. onlinelibrary.wiley.com

---

Causes and risk factors

1. Ultraviolet (UV) sunlight – chronic sun exposure damages DNA in skin cells over many years, raising the chance of SCC in situ. Tanning beds do the same. PMC

2. Older age – risk rises with age because sun damage accumulates and repair systems slow down. PMC

3. Fair skin, light eyes, red or blond hair – less protective melanin means more UV damage. PMC

4. Male sex – men have a slightly higher risk due to sun and occupational exposure patterns. PMC

5. Immunosuppression (organ transplant, chronic steroids, hematologic cancers) – the immune system clears abnormal cells less well, so precancers grow. PMC

6. Human papillomavirus (HPV) – high-risk HPV types especially affect genital and periungual skin; evidence is strongest for genital sites and variable elsewhere. Medscape+2PubMed+2

7. Arsenic exposure (past contaminated water or medicines) – causes multiple keratinocyte cancers including Bowen disease. PMC

8. Prior radiation to the skin – ionizing radiation can trigger long-term DNA injury and in-situ SCC. PMC

9. Chronic wounds and scars – long-standing ulcers, burns, or scars can turn into SCC; in-situ change may be seen at edges. PMC

10. Field cancerization / actinic damage – large sun-damaged areas sprout multiple precancers including SCCIS. PMC

11. Photosensitizing treatments (e.g., high-dose PUVA in the past) – can raise keratinocyte cancer risk after heavy cumulative exposure. PMC

12. Genetic DNA-repair disorders (e.g., xeroderma pigmentosum) – very high risk because UV damage is not repaired. Cancer.gov

13. Albinism – very low melanin makes skin highly UV-sensitive; SCCIS may occur early. PMC

14. Chronic inflammatory dermatoses (e.g., lichen planus, lupus scars) – long inflammation may predispose to SCC in some sites. PMC

15. Smoking – linked to keratinocyte cancers and lip SCC; contributes to field damage. PMC

16. HPV-related sexual exposures – relevant for glans penis, vulva, perianal, and periungual disease. Medscape+1

17. Occupational sun (construction, farming, fishing) – many years outdoors increases risk. PMC

18. Previous skin cancer – a history of any keratinocyte cancer raises the chance of new SCCIS in the same sun-damaged fields. PMC

19. Chronic HPV-related nail infections/trauma – can precede periungual SCCIS. onlinelibrary.wiley.com

20. Impaired immune surveillance with aging or disease – general decline in anti-tumor immunity allows atypical cells to persist. PMC

---

Common symptoms and signs

1. A stubborn red, scaly patch that does not go away for months. It often looks like eczema or psoriasis but keeps returning to the same spot. ACD

2. Well-outlined plaque with sharp edges; the center may be slightly thick or crusted. PMC

3. Slow growth over months to years, usually without sudden changes. PMC

4. Rough, dry surface that flakes easily and may crack or bleed a little. bad.org.uk

5. Mild itch or tenderness, but many lesions are painless. bad.org.uk

6. Color changes – pink, red-brown, or even dark (pigmented variant). DermNet®

7. Sun-exposed location – face, scalp, ears, neck, forearms, shins; but any skin can be involved. PMC

8. Single or multiple spots in a field of sun damage (freckling, actinic keratoses). PMC

9. Crust that reforms after picking, because the abnormal surface keeps producing scale. bad.org.uk

10. No deep hardness at the base (little or no “induration”), which helps distinguish in-situ from invasive SCC. msdmanuals.com

11. Genital lesions (velvety red patch on glans or prepuce) in erythroplasia of Queyrat. Medscape

12. Under-nail changes such as a persistent red streak (erythronychia), warty edge, or pain near the nail fold in nail-unit SCCIS. onlinelibrary.wiley.com

13. Non-healing “eczema” that resists steroid creams or keeps recurring in the same location. bad.org.uk

14. Occasional minor bleeding after rubbing or washing. bad.org.uk

15. Cosmetic concern from a visible patch that is enlarging or changing texture. bad.org.uk

---

Diagnostic tests

A) Physical examination (bedside assessment)

1. Full-skin visual inspection – the clinician looks carefully at the patch: color, borders, scale, and any ulceration; SCC in situ often shows a well-demarcated, scaly plaque. This first step guides whether a biopsy is needed. PMC

2. Palpation for induration – the clinician feels the base. In SCCIS the base is usually soft or only slightly thick; a firm, fixed base suggests invasion and changes management. msdmanuals.com

3. Measurement and photographic mapping – size is recorded and photos are taken to track slow growth or response to treatment, as SCCIS often changes gradually. bad.org.uk

4. Regional lymph-node check – even though SCCIS does not invade, nodes are briefly palpated; if a lesion is long-standing or there is doubt about invasion, enlarged nodes prompt deeper work-up. PMC

5. Anogenital/oral exam when relevant – because HPV-related in-situ disease can be multifocal, nearby mucosal sites may be examined when the primary lesion is genital or perianal. Medscape

B) “Manual” office maneuvers

6. Diascopy (glass slide pressure) – gentle pressure blanches blood from the surface; persistent redness suggests true epidermal change rather than simple vessel dilation, helping distinguish inflammatory rashes from neoplasia. msdmanuals.com

7. Gentle curettage of surface scale – light scraping shows how easily the hyperkeratotic crust lifts and whether pinpoint bleeding occurs; it also permits a cleaner biopsy of the active margin. msdmanuals.com

8. KOH skin scraping (to exclude tinea) – bedside scraping tested with potassium hydroxide helps rule out fungal infection that can mimic scaly plaques before biopsy in tricky cases. msdmanuals.com

C) Laboratory & pathological tests (the gold standard group)

9. Shave biopsy – removes the raised portion across the lesion; pathology looks for full-thickness epidermal atypia without dermal invasion, which confirms SCC in situ. msdmanuals.com

10. Punch biopsy – takes a small cylindrical core that includes the epidermis and superficial dermis. It is helpful on flat plaques or to sample the thickest, most abnormal area. msdmanuals.com

11. Excisional biopsy – removes the entire small lesion with a margin when feasible; gives the most complete sample and can be both diagnostic and curative in selected cases. Cancer.gov

12. Routine histopathology (H&E) – the pathologist reports disordered architecture and atypical keratinocytes involving the full epidermal thickness, parakeratosis, and no invasion. This pattern defines SCCIS. msdmanuals.com

13. Immunohistochemistry (e.g., p16, Ki-67, p53) – can support diagnosis or suggest HPV-driven disease (p16 “block” positivity) and quantify proliferation (Ki-67). Useful in special sites or variants. DermNet®

14. HPV DNA testing (PCR) in genital/periungual sites – sometimes ordered when the result will guide counseling or therapy; positivity supports an HPV-related pathway. DermNet®

15. Margin assessment with frozen section – during excision, frozen-section reading can confirm that the atypical cells are fully removed, reducing recurrence. Cancer.gov

16. Mohs micrographic surgery frozen sections – for special areas (face, nail unit, genitalia), real-time microscopic mapping ensures complete clearance while saving healthy tissue. Cancer.gov

D) Electrodiagnostic tests (clarification)

17. Electrodiagnostic studies (EMG/NCS) – not used for SCC in situ because the disease is limited to the epidermis and does not affect nerves. This entry is included only to clarify that such tests are not indicated. PMC

E) Imaging and non-invasive optical tools

18. Dermoscopy – a handheld scope shows surface and pigment patterns (e.g., glomerular vessels, scale). It improves clinical accuracy and helps target the biopsy site. PMC

19. Reflectance confocal microscopy (RCM) – non-invasive, near-histologic imaging that can reveal atypical keratinocytes and architectural disorder; useful when trying to avoid or guide biopsy. PMC

20. Optical coherence tomography (OCT) / High-frequency ultrasound – cross-sectional imaging to estimate thickness and check for features suggesting invasion; chosen in select centers. Cross-sectional imaging like MRI/CT or PET-CT is not routine for pure SCCIS but may be used if invasion or spread is suspected. Lymph-node ultrasound can be considered when nodes feel enlarged. PMC

Non-pharmacological treatments (therapies & other measures)

1. Surgical excision (standard excision). The lesion is cut out with a margin and the wound closed. It gives high cure rates and is preferred when pathology confirmation of clear margins is essential or when other methods failed. Scars are possible but predictable. PMC+1

2. Curettage with electrodessication. The tumor is gently scraped, then the base is heat-treated to destroy residual cells. It’s quick and inexpensive for well-selected, superficial plaques; cosmetic results vary on the legs. PMC+1

3. Mohs micrographic surgery (select cases). Layer-by-layer removal with immediate microscopic margin control; generally reserved when tissue sparing is critical (e.g., face) or after recurrences. Often unnecessary for typical SCC in situ but valuable for complex sites. Cancer.gov

4. Cryotherapy. A short freeze-thaw cycle with liquid nitrogen destroys atypical cells. It’s convenient and office-based but can scar or cause dyspigmentation; effectiveness may be lower than PDT for some lesions. cochrane.org

5. Ablative laser (e.g., CO₂, Er:YAG). Laser vaporizes diseased epidermis with hemostasis. Useful for flat, thin plaques or field disease; healing requires wound care, but cosmesis can be excellent. MDPI

6. Conventional photodynamic therapy (PDT) with red/blue light. After applying a photosensitizer, the area is illuminated to selectively kill tumor cells. Multiple reviews find high clearance and often better cosmesis than cryotherapy/5-FU in Bowen disease. PMC+1

7. Daylight-PDT (for suitable climates/sites). Uses natural daylight instead of in-office lamps—less pain, similar efficacy for AK and often used in field cancerization; selected centers adapt it for SCC in situ. PMC

8. Radiotherapy (selected patients). Low-dose superficial radiation can treat difficult lesions when surgery/PDT aren’t feasible, especially in frail patients; long-term skin changes can occur. MDPI

9. Close monitoring after biopsy (“watchful waiting”) in select, high-risk surgical patients. Not standard, but very frail patients with small residual disease sometimes choose observation with strict follow-up given the slow growth of many plaques. PMC

10. Wound care optimization. For legs or large treated fields, meticulous after-care (gentle cleansing, petrolatum, non-stick dressings) speeds re-epithelialization and reduces infection. PMC

11. Sun protection counseling. Daily broad-spectrum SPF and UV-avoidance decrease new UV-induced lesions (“field cancerization”) and protect healing skin. Use SPF 30+ broad-spectrum, protective clothing, hats, and shade. American Academy of Dermatology+1

12. Field mapping and staged therapy planning. When multiple plaques and actinic damage coexist, clinicians plan staged procedures or combine topical therapy with PDT to limit downtime and improve clearance. dynamed.com

13. Smoking cessation support. Stopping nicotine improves skin vascularity and wound healing after procedures; counseling and support programs are recommended. PMC

14. Compression/edema control (lower legs). Edema worsens healing and recurrence risk on the shins; appropriate compression and vascular optimization support outcomes after local therapies. PMC

15. Scar-minimization strategies. Silicone gel, sun avoidance, and staged procedures reduce visible scarring—important for face or cosmetically sensitive sites. PMC

16. Patient self-exams with photo-tracking. Monthly skin checks and smartphone photos help detect recurrences or new plaques early; prompt review by a dermatologist is key. American Academy of Dermatology

17. Multidisciplinary review for special sites. For nail, genital, or peri-anal in situ SCC, coordination with surgical oncology/gynecology/urology ensures optimal function and cosmesis. Cancer.gov

18. Allergy/irritant management during field therapy. Anticipatory guidance for redness, crusting, and pain (e.g., petrolatum, temporary rest days) improves adherence to topical protocols. FDA Access Data+1

19. Recurrence-risk stratification and tailored follow-up. Site, size, immune status, and prior treatments guide follow-up intervals to catch rare progressions to invasive SCC. PMC

20. Patient education materials. Handouts and reputable websites (AAD, NCI) improve understanding and adherence, which directly impacts outcomes and cosmetic results. Cancer.gov+1

---

Drug treatments

Important: In the U.S., several drugs below are FDA-approved for actinic keratoses (AK) or other keratinocyte cancers, not specifically for “SCC in situ.” In practice, dermatologists often use them off-label for Bowen disease when appropriate. Always follow a dermatologist’s plan and the FDA label. Citations link to accessdata.fda.gov labels.

1. Fluorouracil 5% cream (Efudex) — antimetabolite; field/lesion therapy (off-label for SCC in situ).
   Dose/Time: Typically twice daily for 2–6 weeks on limited areas (follow label for AK; off-label regimens vary). Purpose/Mechanism: Inhibits thymidylate synthase, causing selective death of rapidly dividing atypical keratinocytes, useful for field cancerization around a plaque. Common effects: Erythema, crusting, pain, photosensitivity; severe irritation may prompt rest days. FDA Access Data

2. Imiquimod 5% cream (Aldara) — immune response modifier; off-label for SCC in situ.
   Dose/Time: AK/BCC schedules vary on label; Bowen regimens often 3–7 nights/week for several weeks under supervision. Purpose/Mechanism: Activates TLR-7 to trigger local interferon and cell-mediated tumor clearance; good cosmesis but inflammatory reactions are expected. Side effects: Erythema, erosion, flu-like symptoms; strict sun protection. FDA Access Data

3. Aminolevulinic acid 20% solution (Levulan Kerastick) + PDT — photosensitizer for PDT; commonly used for field disease.
   Dose/Time: Apply, incubate, then illuminate with blue light per label; sessions may be repeated. Purpose/Mechanism: Converts to protoporphyrin IX in atypical cells; light activation generates reactive oxygen species that selectively destroy dysplastic epidermis. Effects: Burning during illumination, erythema; post-procedure photoprotection is critical. FDA Access Data

4. Tirbanibulin 1% ointment (Klisyri) — microtubule/tyrosine-kinase signaling inhibitor; FDA-approved for AK on face/scalp; off-label for SCC in situ cases under specialist care.
   Dose/Time: Once daily x 5 days for a small field (per label). Purpose/Mechanism: Disrupts microtubules and Src signaling, inducing apoptosis in atypical keratinocytes. Effects: Local erythema, scaling; typically short course improves adherence. FDA Access Data+1

5. Diclofenac 3% gel (Solaraze) — topical NSAID for AK; sometimes used around SCC in situ fields.
   Dose/Time: Twice daily for 60–90 days (per label). Purpose/Mechanism: COX-2 inhibition may reduce prostaglandin-driven proliferation in actinic dysplasia. Effects: Local irritation; avoid during pregnancy late trimester; systemic NSAID warnings apply. FDA Access Data+1

6. Cemiplimab (Libtayo) IV — PD-1 inhibitor for advanced cSCC; not for routine SCC in situ.
   Dose/Time: 350 mg IV q3 weeks for unresectable/metastatic cSCC (per label). Purpose/Mechanism: Releases antitumor T-cell responses; reserved for invasive/advanced disease after specialist staging. Effects: Immune-related AEs (thyroiditis, colitis, pneumonitis). FDA Access Data

7. Cosibelimab (Unloxcyt) IV — PD-1 inhibitor for locally advanced/metastatic cSCC; not for SCC in situ.
   Dose/Time: Per label under oncology guidance. Purpose/Mechanism: Immune checkpoint blockade; used when surgery/radiation are not curative. Effects: Similar immune-related risks as other PD-1 agents. FDA Access Data+1

8. Fluorouracil 0.5% cream (various brands) — lower-strength 5-FU for AK; occasionally part of combination field therapy.
   Notes: Same antimetabolite mechanism; inflammatory “field reaction” signals activity. Use: Dermatologist-directed off-label protocols for surrounding actinic skin. FDA Access Data

9. Aminolevulinic acid (Levulan) blue-light protocol specifics — label details for timing and illumination device (BLU-U) help standardize outcomes and safety. Use: Strictly follow label timing and post-PDT light avoidance. FDA Access Data

10. (Contextual) Diclofenac 3% gel label warnings — reinforce safe use during prolonged courses used for field disease. Use: Dermatologist may choose diclofenac when milder, longer courses are preferred and cosmesis is paramount. FDA Access Data

If you want, I can expand this section to a full 20-drug compendium (e.g., additional 5-FU/tretinoin combos, tazarotene, calcipotriene-5-FU protocols, other PDT photosensitizers where available, systemic retinoids for chemoprevention in select high-risk patients—with clear off-label flags and FDA label anchors).

---

Dietary molecular supplements

Supplements are adjuncts and never replace definitive lesion therapy. Discuss with your clinician, especially if pregnant, immunosuppressed, or on anticoagulants.

1. Nicotinamide (vitamin B3 amide). In high-risk patients, 500 mg twice daily reduced new non-melanoma skin cancers and actinic keratoses in a 12-month RCT; benefits stop when you stop. Not a treatment for an existing plaque but useful for “field” risk reduction in appropriate adults. New England Journal of Medicine

2. Re-evaluation of nicotinamide in transplant recipients. A 2023 RCT in organ-transplant recipients did not show benefit, underscoring that effects may differ in the heavily immunosuppressed. Use is individualized. New England Journal of Medicine

3. Broad-spectrum photoprotection with diet is not a substitute for sunscreen. Despite online claims, professional bodies emphasize sunscreen/clothing; dietary “natural oils” don’t reliably prevent UV damage. U.S. Food and Drug Administration+1

4. General antioxidant-rich diet (fruits/vegetables). Supports skin health and wound healing after procedures, but evidence for preventing SCC in situ progression is indirect; prioritize procedural therapy and sun safety. Cancer.gov

5. Vitamin D from food/supplements (when deficient). Correcting deficiency supports general health; obtain vitamin D safely rather than through intentional UV. U.S. Food and Drug Administration

6. Omega-3 fatty acids. Modest anti-inflammatory benefits support overall skin health; evidence isn’t disease-specific—use as part of heart-healthy diet. Cancer.gov

7. Adequate protein intake. Helps post-procedure healing; prioritize lean proteins if undergoing surgical/ablative care. PMC

8. Hydration. Maintains skin barrier and supports wound healing after field therapies; simple but important. PMC

9. Avoid high-alcohol intake. Excess alcohol has been linked with poor healing and increased skin cancer risk signals; moderation supports outcomes. PMC

10. Avoid beta-carotene megadoses for “sun protection.” No reliable protection and potential harms in smokers; rely on sunscreen/clothing instead. NCBI

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved “immunity-booster,” regenerative, or stem-cell drugs for SCC in situ. Immune checkpoint inhibitors (e.g., cemiplimab, cosibelimab) are life-saving for advanced cutaneous SCC—not for routine in situ disease—and carry serious immune-related risks. Any “stem cell” product marketed for skin cancer outside a clinical trial should be avoided. If progression to invasive SCC is suspected, referral to a cutaneous oncologist is crucial. FDA Access Data+1

---

Surgeries/procedures (what’s done & why)

1. Standard surgical excision — removes the plaque with a safety margin; chosen for solitary lesions needing histologic margin control or after other therapies fail. Why: highest certainty of complete removal in one visit. PMC

2. Curettage ± electrodessication — scrapes away tumor then cauterizes base. Why: fast, cost-effective for thin plaques in non-critical cosmetic sites. PMC

3. Mohs micrographic surgery — staged excision with on-the-spot microscopy. Why: tissue-sparing with maximal margin certainty in delicate areas or recurrences. Cancer.gov

4. Ablative laser (CO₂/Er:YAG) — vaporizes diseased epidermis. Why: precise removal with good hemostasis; helpful for broad, superficial plaques. MDPI

5. Photodynamic therapy (PDT) — drug-light procedure destroying atypical cells. Why: excellent cosmesis for flat plaques/field disease with strong efficacy data in Bowen disease. PMC+1

---

Practical preventions

1. Daily broad-spectrum SPF 30+ and reapply; combine with hats, UPF clothing, shade. American Academy of Dermatology+1

2. Avoid tanning beds and intentional UV exposure. American Academy of Dermatology

3. Monthly self-skin checks; photograph plaques and treated sites. American Academy of Dermatology

4. Scheduled dermatologist follow-ups (e.g., 6–12 months, individualized). PMC

5. Manage immunosuppression with your specialist (if possible) to lower progression risk. PMC

6. Nicotinamide 500 mg BID in appropriate high-risk adults after clinician approval. New England Journal of Medicine

7. Cover healing skin after procedures; follow wound-care instructions. PMC

8. Quit smoking; improves skin healing and long-term risk. PMC

9. Protect scars from sun (SPF + hats) to prevent pigment changes. American Academy of Dermatology

10. Learn credible info sources (NCI, AAD) and avoid misinformation about “natural sun protection.” Cancer.gov+1

---

When to see a doctor

See a dermatologist promptly for any new or changing, scaly red plaque; a nonhealing sore; pain, bleeding, or thickening of a known lesion; rapid growth; or if a previously treated area shows new scaling or color change. People with organ transplants, chronic lymphocytic leukemia, HIV, or on long-term immunosuppression need earlier evaluation and closer follow-up due to higher risk of progression. PMC

---

What to eat & what to avoid

Eat: a balanced diet rich in colorful fruits/vegetables, lean proteins, whole grains, and healthy fats (support healing after procedures).

Avoid/limit: excessive alcohol and ultra-processed foods; do not use dietary oils as “sunscreen.” If vitamin D is low, replete with diet/supplement—not UV. Supplements never replace sunscreen/clothing. U.S. Food and Drug Administration+1

---

FAQs

1. Is SCC in situ dangerous? It’s non-invasive and highly curable, but a minority can progress to invasive SCC if ignored—so treat and follow up. DermNet®

2. What’s the best treatment? Depends on size, site, number, and patient factors; surgery, PDT, and select topicals each have roles; cosmesis often favors PDT/topicals. Cancer.gov+1

3. Does it scar? Any therapy can scar; PDT and topicals generally offer better cosmetic outcomes than freezing or surgery for flat plaques. cochrane.org

4. Can creams cure it? Yes—5-FU or imiquimod can clear many lesions when used correctly (often off-label), but they cause a predictable inflammatory reaction during treatment. FDA Access Data+1

5. Is PDT painful? Brief burning during light exposure is common; cosmesis is often excellent. FDA Access Data

6. Will sunscreen really help? Yes—daily broad-spectrum SPF 30+ plus clothing/hat reduce new UV-driven lesions; sunscreen myths are widespread online. American Academy of Dermatology+1

7. Can it come back? Recurrences can occur; keep regular follow-ups and self-checks. PMC

8. Do I need Mohs? Often no for typical SCC in situ; Mohs is reserved for special sites or recurrences. Cancer.gov

9. Are immune drugs used? Checkpoint inhibitors (cemiplimab, cosibelimab) are for advanced cSCC—not routine in situ disease. FDA Access Data+1

10. Is nicotinamide helpful? In high-risk adults, 500 mg twice daily reduced new keratinocyte cancers over 12 months, but benefits stop after discontinuation and may not extend to transplant recipients. New England Journal of Medicine+1

11. What if I’m pregnant? Management is individualized; many topical agents are avoided. Discuss timing and safest procedures with your dermatologist/OB. PMC

12. How is diagnosis made? By skin biopsy—pathology confirms atypical keratinocytes throughout the epidermis without invasion. DermNet®

13. Can I just watch it? Observation is generally not advised except in exceptional, frail patients with close follow-up. PMC

14. What about cryotherapy at home? Do not attempt; medical-grade cryotherapy is far colder and targeted, with post-care guidance. cochrane.org

15. Where can I read more? AAD cSCC guideline overview and NCI PDQ provide clinician-vetted summaries. American Academy of Dermatology+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 31, 2025.